Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Ribosome biogenesis and protein synthesis are fundamental rate-limiting steps for cell
growth and proliferation. The ribosomal proteins (RPs), comprising the structural parts of the …
growth and proliferation. The ribosomal proteins (RPs), comprising the structural parts of the …
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
NG Daver, A Maiti, TM Kadia, P Vyas, R Majeti, AH Wei… - Cancer discovery, 2022 - AACR
TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Abstract Tumor protein p53 (TP53) is the most frequently mutated gene in cancer,. In
patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high …
patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high …
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
G Garcia‐Manero - American journal of hematology, 2023 - Wiley Online Library
Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
AS Sperling, VA Guerra, JA Kennedy… - Blood, The Journal …, 2022 - ashpublications.org
There is a growing body of evidence that therapy-related myeloid neoplasms (t-MNs) with
driver gene mutations arise in the background of clonal hematopoiesis (CH) under the …
driver gene mutations arise in the background of clonal hematopoiesis (CH) under the …
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic
and lymphoid tissues was last updated in 2008. Since then, there have been numerous …
and lymphoid tissues was last updated in 2008. Since then, there have been numerous …
Genetics of MDS
S Ogawa - Blood, The Journal of the American Society of …, 2019 - ashpublications.org
Our knowledge about the genetics of myelodysplastic syndromes (MDS) and related
myeloid disorders has been dramatically improved during the past decade, in which …
myeloid disorders has been dramatically improved during the past decade, in which …
Lenalidomide induces ubiquitination and degradation of CK1α in del (5q) MDS
Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with
deletion of chromosome 5q (del (5q)). Here, we demonstrate that lenalidomide induces the …
deletion of chromosome 5q (del (5q)). Here, we demonstrate that lenalidomide induces the …
Treatment of MDS
U Platzbecker - Blood, The Journal of the American Society of …, 2019 - ashpublications.org
The heterogeneous nature of myelodysplastic syndromes (MDS) demands a complex and
personalized variety of therapeutic approaches. Among them, allogeneic hematopoietic …
personalized variety of therapeutic approaches. Among them, allogeneic hematopoietic …
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS).
Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic …
Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic …